I agree that this site is using cookies. You can find further informations here.
X
Lythgoe, Mark P.
475  results:
Search for persons X
?
1

Shortages of essential cancer medicines: who is responsible..:

Jenei, Kristina ; Lythgoe, Mark P ; Vokinger, Kerstin N
The Lancet Oncology.  25 (2024)  1 - p. 23-26 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Lifileucel: the first cellular therapy approved for solid t..:

Julve, Max ; Lythgoe, Mark P. ; Larkin, James.
Trends in Cancer.  10 (2024)  6 - p. 475-477 , 2024
Link: https://doi.org/10.1016/..
 
?
3

The evolving posology and administration of immune checkpoi..:

Hadfield, Matthew J. ; Benjamin, David J. ; Krell, Jonathan..
Trends in Cancer.  10 (2024)  7 - p. 579-583 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Implications of FDA's marketing authorization of hereditary..:

Benjamin, David J. ; Lythgoe, Mark P. ; Rezazadeh Kalebasty, Arash
Journal of Cancer Policy.  40 (2024)  - p. 100478 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Access divergence to new cancer medicines in the United Kin..:

Lythgoe, Mark P. ; Blagden, Sarah ; Stanway, Susannah.
European Journal of Cancer.  207 (2024)  - p. 114131 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Hormonal treatment for newly diagnosed metastatic prostate ..:

Benjamin, David J. ; Shrestha, Anshu ; Fellman, Dimitra...
Prostate Cancer and Prostatic Diseases.  , 2023
Link: https://doi.org/10.1038/..
 
?
7

Adjuvant checkpoint inhibitor trials: Is disease-free survi..:

Khaki, Ali Raza ; Lythgoe, Mark P. ; Prasad, Vinay
Journal of Cancer Policy.  35 (2023)  - p. 100402 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Financial toxicity from newly approved second‐/third‐line a..:

Benjamin, David J. ; Lythgoe, Mark P. ; Rezazadeh, Arash
BJU International.  131 (2023)  6 - p. 691-693 , 2023
Link: https://doi.org/10.1111/..
 
?
9

The rise of immuno-oncology in China: a challenge to wester..:

Lythgoe, Mark P ; Lewison, Grant ; Aggarwal, Ajay...
The Lancet Oncology.  24 (2023)  5 - p. 439-441 , 2023
Link: https://doi.org/10.1016/..
 
?
10

The FDA's latest draft guidance on accelerated approvals — ..:

Benjamin, David J. ; Lythgoe, Mark P.
Nature Reviews Clinical Oncology.  20 (2023)  9 - p. 577-578 , 2023
Link: https://doi.org/10.1038/..
 
?
11

Outsourcing UK regulatory decisions—a double-edged sword?:

Lythgoe, Mark P ; Sullivan, Richard
The Lancet.  402 (2023)  10395 - p. 24-25 , 2023
Link: https://doi.org/10.1016/..
 
?
12

The evidence base of US Food and Drug Administration approv..:

Gloy, Viktoria ; Schmitt, Andreas M. ; Düblin, Pascal...
International Journal of Cancer.  152 (2023)  12 - p. 2474-2484 , 2023
Link: https://doi.org/10.1002/..
 
?
13

UK oncology approvals in 2022: global regulatory collaborat..:

Lythgoe, Mark P ; Sullivan, Richard ; Blagden, Sarah
The Lancet Oncology.  24 (2023)  9 - p. 963-966 , 2023
Link: https://doi.org/10.1016/..
 
?
14

Repositioning canakinumab for non-small cell lung cancer—im..:

Lythgoe, Mark P. ; Prasad, Vinay
British Journal of Cancer.  127 (2022)  5 - p. 785-787 , 2022
Link: https://doi.org/10.1038/..
 
?
15

The last word to new FDA draft guidance for cancer clinical..:

Lythgoe, Mark P. ; Prasad, Vinay
Journal of Cancer Policy.  31 (2022)  - p. 100322 , 2022
Link: https://doi.org/10.1016/..
 
1-15